Guselkumab,Golimumab
Janssen
['janssen']
at #uegweek, our new data demonstrate induction treatment with combination therapy followed by switching to monotherapy was more effective than monotherapy alone at 38 weeks in the treatment of adults living with #ulcerativecolitis. learn more: 
At Janssen, we never stop working toward a future where disease is a thing of the past. Channel run by Janssen Global Services LLC, NJ, USA.